TriangleMRI-guided adaptive stereotactic… (NCT07223307)
MRI-guided adaptive stereotactic ablative body radiotherapy (SABR) trial for Liver Cancer (NCT07223307). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with hepatocellular cancer, intrahepatic bile-duct cancer or liver metastases, with Child-Pugh A liver function. Prior radioembolization or overlapping radiation excludes participation. Patients must tolerate MRI and hold their breath longer than 15 seconds.
The idea: use MRI to guide and adapt a single external-beam radiation treatment of 30–40 gray. Contrast helps show the tumor; breath holds limit motion. Planning aims to target the tumor while limiting nearby tissue exposure.
This phase 2 study plans 62 patients. Stanford in Palo Alto lists the sole recruiting US location.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.